Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C78854
http://purl.obolibrary.org/obo/NCIT_C78854
|
|---|---|
| Preferred Name | Dinaciclib |
| Definitions |
A pyrazolo[1,5-a]pyrimidine with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9; inhibition of CDK1 and CDK2 may result in cell cycle repression and tumor cell apoptosis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A pyrazolo[1,5-a]pyrimidine with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9; inhibition of CDK1 and CDK2 may result in cell cycle repression and tumor cell apoptosis. |
|---|---|
| prefLabel | Dinaciclib
|
| label | Dinaciclib
|
| PDQ_Closed_Trial_Search_ID | 612855
|
| code | C78854
|
| Has_Target | |
| prefixIRI | NCIT:C78854
|
| in_subset |
See more
See less
|
| Display_Name | Dinaciclib
|
| Preferred_Name | Dinaciclib
|
| FDA_UNII_Code | 4V8ECV0NBQ
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C21H28N6O2
|
| Maps_To | Dinaciclib
|
| CAS_Registry | 779353-01-4
|
| NCI_Drug_Dictionary_ID | 612855
|
| Legacy Concept Name | CDK_Inhibitor_SCH_727965
|
| type | |
| ALT_DEFINITION | A substance being studied in the treatment of advanced melanoma (a type of skin cancer) and other types of cancer. It blocks cell division and may cause cancer cells to die. It is a type of cyclin-dependent kinase inhibitor.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 612855
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C2698720
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |